GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US clinical stage caner drug developer Theriva Biologics revealed that the US Food and Drug Administration (FDA) has granted Rare Pediatric Drug designation (RPDD) for VCN-01 for the treatment of retinoblastoma. 1 August 2024
Eisai and Biogen have announced that Israel has approved their Alzheimer's treatment, Leqembi (lecanemab), adding to nods in the USA, Japan, China, South Korea, and Hong Kong. 12 July 2024
Contract research and development organization (CDMO) Emergent BioSolutions has announced that Johnson & Johnson will pay $50 million to resolve claims linked to a terminated manufacturing deal for the latter’s COVID-19 vaccine. 11 July 2024
Japan’s Eisai and US biotech Biogen have announced that the Department of Health in Hong Kong has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for treatment of Alzheimer’s disease (AD). 11 July 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has announced that its polyclonal Treg cell therapy PTG-007 demonstrated significant insulin secretion restoration in early-onset type-1 diabetes (T1D) patients, as well as a longer period of disease remission compared to a control group receiving standard-of-care. 24 June 2024
Indian drugmaker Cipla announced that its wholly-owned subsidiary in the UK, Cipla (EU) Limited, will invest an additional 3 million euros ($3.2 million) in Ethris GmbH, a German firm delivering mRNAs directly to the respiratory system. 19 June 2024
Dutch autoimmune diseases specialist Argenx announced that results from the Phase II ALPHA study of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) show that treated patients had no clinically meaningful improvement compared to placebo on the total Malmö POTS symptom (MaPS) score and COMPASS31. 17 June 2024
The US Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for monthly Leqembi (lecanemab-irmb) intravenous (IV) maintenance dosing. 10 June 2024
The European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved Chimeric Antigen Receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) from Gilead Sciences’ Kite subsidiary. 6 June 2024
Avacta Group, a developer of Affimer biotherapeutics and research reagents, has agreed a strategic partnership with the cell line development company Selexis. 20 June 2019
US biotech major Amgen and the University of Washington's Institute for Protein Design (IPD) today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to the search for new medicines. 20 June 2019
Japanese conglomerate Fujifilm Corp has signed an agreement to invest 300 million yen ($2.8 million) into a biotech venture, PuREC Co, through underwriting its third-party allocation of shares. 20 June 2019
US biotech major Gilead Sciences has struck a deal with privately-held Nurix to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. 19 June 2019
Onpattro (patisiran), the gene-silencing drug from US biotech Alnylam, has been approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy in Japan. 19 June 2019
Boston, USA-based cell therapy developer Gamida Cell and Switzerland’s Lonza today announced that they have entered into a strategic manufacturing agreement. 19 June 2019
Chinese cancer specialist BeiGene has entered into a second collaboration with SpringWorks Therapeutics, a spin-out from US pharma giant Pfizer. 18 June 2019
Much of the dialogue surrounding Roche’s oncology drugs is currently about the big-selling products at the end of their patent life, but the company has provided a timely reminder that its new innovations are a big deal too. 18 June 2019
Merck & Co has been granted a new label update for its immuno-oncology blockbuster, Keytruda (pembrolizumab), in metastatic small cell lung cancer (SCLC). 18 June 2019
Having already backed out of an option on a Parkinson’s disease program in 2017, Sanofi Genzyme is now pulling further out of its collaboration with USA-based Voyager Therapeutics, as the companies yesterday announced a restructuring of their gene therapy relationship. 18 June 2019
Tumor drug resistance specialist Deciphera Pharmaceuticals has inked a deal with Shanghai-based Zai Lab to advance the development and commercialization of ripretinib in China. 18 June 2019
Belgian immunotherapies developer Imcyse today announces that it has raised 35 million euros ($39.5 million) in a Series B financing round and through other channels. Imcyse is a spin-off from Belgium’s Katholieke Universiteit Leuven (KUL). 18 June 2019
At first glance, an observer might have predicted that shares in VBI Vaccines would have shot up based on the results of its PROTECT Phase III study, rather than to decline by more than 60% as they did on Monday morning. 17 June 2019
AstraZeneca could be on course to gain another indication with Calquence (acalabrutinib), a Bruton tyrosine kinase (BTK) inhibitor that already has accelerated US approval for mantle cell lymphoma (MCL). 17 June 2019
CASI Pharmaceuticals has revealed it has signed a license agreement for exclusive worldwide license and commercialization rights to an autologous anti-CD19 T-cell therapy product (CNCT19) from Juventas Cell Therapy, a China-based domestic company located in Tianjin City, China. 17 June 2019
The global cell therapy market size is expected to reach a value of $7.92 billion by 2025, rising at a compound annual growth rate (CAGR) of 5.34% during the forecast period. 17 June 2019
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference. 17 June 2019
US pharma giant Pfizer today announced that it will acquire Array BioPharma, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. 17 June 2019